ArticleBMC chemistry2025
Stability indicating green micellar liquid chromatographic method for simultaneous analysis of Metformin and dapagliflozin in their tablets.
Article in BMC chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A green micellar liquid chromatography (MLC) technique was established for simultaneous determination of dapagliflozin (DAP) and Metformin HCl (MET) in their pure and tablet dosage forms. Stability studies were carried out for both drugs using different five degradation conditions. The chromatographic separation was achieved using BDS Thermo-Hypersil C8 (150 mm x 4.6 mm, 5 μm) column and hybrid micellar mobile phase composed of 50 gm of sodium lauryl sulphate in 500 mL purified water with 100mL of 2-Propanol and 3 mL triethylamine and then completed with purified water to 1000mL, and the mobile phase pH was 3.3. The (PDA) detector was used at 223 nm, 40 °C column temperature, 1mL/min flow rate and 20µL injection volume. The retention times of DAP and MET were (5.37 ± 0.4 min) and (7.64 ± 0.2 min), respectively. Linearity was constructed in ranges of (0.2-7 µg/mL) for DAP and (50-700 µg/mL) for MET. Mean percentage recoveries of DAP and MET were 99.88%±0.53 and 100.034%±0.60, respectively indicates good accuracy. The developed approach was validated according to ICH guidelines and efficiently applied for the analysis of DAP and MET in Dexigloflozin plus
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.